Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.72 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.64 |
| ▸ | GCGR | P47871 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31199036 | 1.00 | MAPT (0.74) | MAPTNTRK1HDAC3HDAC4HDAC1 | |
| SCHEMBL14223790 | 1.00 | MAPT (0.74) | MAPTNTRK1HDAC3HDAC4HDAC1 | |
| SCHEMBL6568243 | 1.00 | MAPT (0.74) | MAPTNTRK1HDAC3HDAC4HDAC1 | |
| SCHEMBL28426096 | 0.92 | MAPT (0.71) | MAPTNTRK1HDAC3HDAC4HDAC1 | |
| SCHEMBL6749929 | 0.88 | NOX4 (0.69) | MAPTNTRK1 | |
| SCHEMBL19283300 | 0.88 | MAPT (0.79) | MAPTNTRK1HDAC3HDAC4HDAC1 | |
| SCHEMBL19283298 | 0.88 | MAPT (0.79) | MAPTNTRK1HDAC3HDAC4HDAC1 | |
| SCHEMBL14983946 | 0.88 | NOX4 (0.69) | MAPTNTRK1 | |
| SCHEMBL6749927 | 0.88 | NOX4 (0.69) | MAPTNTRK1 | |
| SCHEMBL28429011 | 0.87 | MAPT (0.77) | MAPTNTRK1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110963-A1 | Novel hydrazones | ARPIDA AG (CH) | 2004-06-10 | — | — | US | claimed |
| US-20040110963-A1 | Novel hydrazones | ARPIDA AG (CH) | 2004-06-10 | — | — | US | disclosed |
| EP-1404644-A2 | NOVEL HYDRAZONES | Arpida AG, (CH) | 2004-04-07 | — | — | EP | disclosed |
| WO-2002070464-A2 | HYDRAZONES AND THEIR THERAPEUTIC USE | ARPIDA AG (CH) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110963-A1 | Novel hydrazones | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK1, MPO | MAPT 3140/4885NTRK1 4662/4885HDAC3 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.